After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last...
AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises
After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels...
Author: Fierce Biotech
Read Original Article